This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Xiao Feng, Ph.D.
Vice President, Head of Research at Zenas BioPharma
Speaker

Profile

Dr. Xiao Feng is Vice President, Head of Research at Zenas BioPharma. Prior to joining Zenas, he served as Executive Director, Toxicology and DMPK at Boston Pharmaceuticals. Previously, Dr. Feng was the Senior Director of Toxicology and DMPK at Corbus Pharmaceuticals.

Dr. Feng has over 20 years of experience in the biopharmaceutical industry from early discovery to late stage drug development support including commercialization to life cycle management.

He has led Nonclinical Development for multiple programs from IND-enabling through successful registration. Dr. Feng received a Ph.D. in Cell Biology from Duke University, and an M.S. and B.S. in Genetics and Biology, respectively, from Fudan University.

Agenda Sessions

  • Obexelimab: A Differentiated B cell Targeted Antibody for Treatment of Autoimmune Diseases

    3:30pm